Global Rare Hemophilia Factors Market to Reach $471.2 Million by 2030
The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet.
New York, May 08, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Rare Hemophilia Factors Industry" - https://www.reportlinker.com/p06032737/?utm_source=GNW
Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China’s already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.
Global Rare Hemophilia Factors Market to Reach $471.2 Million by 2030
In the changed post COVID-19 business landscape, the global market for Rare Hemophilia Factors estimated at US$258.6 Million in the year 2022, is projected to reach a revised size of US$471.2 Million by 2030, growing at aCAGR of 7.8% over the period 2022-2030. Fresh Frozen Plasma, one of the segments analyzed in the report, is projected to record 7.5% CAGR and reach US$224 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Factor Concentrates segment is readjusted to a revised 8.9% CAGR for the next 8-year period.
The U.S. Market is Estimated at $75.7 Million, While China is Forecast to Grow at 7.5% CAGR
The Rare Hemophilia Factors market in the U.S. is estimated at US$75.7 Million in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$83.1 Million by the year 2030 trailing a CAGR of 7.5% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7.2% and 6.7% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 7.3% CAGR.
Select Competitors (Total 42 Featured)
- Baxalta
- Bayer healthcare
- Bio Products Laboratory Ltd
- Biogen
- CSL Behring
- Novo Nordisk
- Pfizer, Inc.
- Shire
- Takeda Pharmaceutical Co. Ltd.
Read the full report: https://www.reportlinker.com/p06032737/?utm_source=GNW
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
Rare Hemophilia Factors - Global Key Competitors Percentage
Market Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for
Players Worldwide in 2022 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
Table 1: World Recent Past, Current & Future Analysis for Rare
Hemophilia Factors by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2022 through 2030 and % CAGR
Table 2: World Historic Review for Rare Hemophilia Factors by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2014 through 2021 and
% CAGR
Table 3: World 16-Year Perspective for Rare Hemophilia Factors
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets for Years 2014, 2023 & 2030
Table 4: World Recent Past, Current & Future Analysis for Fresh
Frozen Plasma by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2022 through
2030 and % CAGR
Table 5: World Historic Review for Fresh Frozen Plasma by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2014 through 2021 and
% CAGR
Table 6: World 16-Year Perspective for Fresh Frozen Plasma by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2014, 2023 & 2030
Table 7: World Recent Past, Current & Future Analysis for
Factor Concentrates by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2022 through 2030 and % CAGR
Table 8: World Historic Review for Factor Concentrates by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2014 through 2021 and
% CAGR
Table 9: World 16-Year Perspective for Factor Concentrates by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2014, 2023 & 2030
Table 10: World Recent Past, Current & Future Analysis for
Cryoprecipitate by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2022 through 2030 and % CAGR
Table 11: World Historic Review for Cryoprecipitate by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2014 through 2021 and
% CAGR
Table 12: World 16-Year Perspective for Cryoprecipitate by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2014, 2023 & 2030
Table 13: World Recent Past, Current & Future Analysis for
Other Treatments by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2022 through 2030 and % CAGR
Table 14: World Historic Review for Other Treatments by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2014 through 2021 and
% CAGR
Table 15: World 16-Year Perspective for Other Treatments by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2014, 2023 & 2030
Table 16: World Rare Hemophilia Factors Market Analysis of
Annual Sales in US$ Thousand for Years 2014 through 2030
III. MARKET ANALYSIS
UNITED STATES
Rare Hemophilia Factors Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in the United States for 2023 (E)
Table 17: USA Recent Past, Current & Future Analysis for Rare
Hemophilia Factors by Treatment - Fresh Frozen Plasma, Factor
Concentrates, Cryoprecipitate and Other Treatments -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2022 through 2030 and % CAGR
Table 18: USA Historic Review for Rare Hemophilia Factors by
Treatment - Fresh Frozen Plasma, Factor Concentrates,
Cryoprecipitate and Other Treatments Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2014 through
2021 and % CAGR
Table 19: USA 16-Year Perspective for Rare Hemophilia Factors
by Treatment - Percentage Breakdown of Value Sales for Fresh
Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other
Treatments for the Years 2014, 2023 & 2030
CANADA
Table 20: Canada Recent Past, Current & Future Analysis for
Rare Hemophilia Factors by Treatment - Fresh Frozen Plasma,
Factor Concentrates, Cryoprecipitate and Other Treatments -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2022 through 2030 and % CAGR
Table 21: Canada Historic Review for Rare Hemophilia Factors by
Treatment - Fresh Frozen Plasma, Factor Concentrates,
Cryoprecipitate and Other Treatments Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2014 through
2021 and % CAGR
Table 22: Canada 16-Year Perspective for Rare Hemophilia
Factors by Treatment - Percentage Breakdown of Value Sales for
Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and
Other Treatments for the Years 2014, 2023 & 2030
JAPAN
Rare Hemophilia Factors Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Japan for 2023 (E)
Table 23: Japan Recent Past, Current & Future Analysis for Rare
Hemophilia Factors by Treatment - Fresh Frozen Plasma, Factor
Concentrates, Cryoprecipitate and Other Treatments -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2022 through 2030 and % CAGR
Table 24: Japan Historic Review for Rare Hemophilia Factors by
Treatment - Fresh Frozen Plasma, Factor Concentrates,
Cryoprecipitate and Other Treatments Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2014 through
2021 and % CAGR
Table 25: Japan 16-Year Perspective for Rare Hemophilia Factors
by Treatment - Percentage Breakdown of Value Sales for Fresh
Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other
Treatments for the Years 2014, 2023 & 2030
CHINA
Rare Hemophilia Factors Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in China for 2023 (E)
Table 26: China Recent Past, Current & Future Analysis for Rare
Hemophilia Factors by Treatment - Fresh Frozen Plasma, Factor
Concentrates, Cryoprecipitate and Other Treatments -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2022 through 2030 and % CAGR
Table 27: China Historic Review for Rare Hemophilia Factors by
Treatment - Fresh Frozen Plasma, Factor Concentrates,
Cryoprecipitate and Other Treatments Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2014 through
2021 and % CAGR
Table 28: China 16-Year Perspective for Rare Hemophilia Factors
by Treatment - Percentage Breakdown of Value Sales for Fresh
Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other
Treatments for the Years 2014, 2023 & 2030
EUROPE
Rare Hemophilia Factors Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Europe for 2023 (E)
Table 29: Europe Recent Past, Current & Future Analysis for
Rare Hemophilia Factors by Geographic Region - France, Germany,
Italy, UK and Rest of Europe Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2022 through 2030 and %
CAGR
Table 30: Europe Historic Review for Rare Hemophilia Factors by
Geographic Region - France, Germany, Italy, UK and Rest of
Europe Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2014 through 2021 and % CAGR
Table 31: Europe 16-Year Perspective for Rare Hemophilia
Factors by Geographic Region - Percentage Breakdown of Value
Sales for France, Germany, Italy, UK and Rest of Europe Markets
for Years 2014, 2023 & 2030
Table 32: Europe Recent Past, Current & Future Analysis for
Rare Hemophilia Factors by Treatment - Fresh Frozen Plasma,
Factor Concentrates, Cryoprecipitate and Other Treatments -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2022 through 2030 and % CAGR
Table 33: Europe Historic Review for Rare Hemophilia Factors by
Treatment - Fresh Frozen Plasma, Factor Concentrates,
Cryoprecipitate and Other Treatments Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2014 through
2021 and % CAGR
Table 34: Europe 16-Year Perspective for Rare Hemophilia
Factors by Treatment - Percentage Breakdown of Value Sales for
Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and
Other Treatments for the Years 2014, 2023 & 2030
FRANCE
Rare Hemophilia Factors Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in France for 2023 (E)
Table 35: France Recent Past, Current & Future Analysis for
Rare Hemophilia Factors by Treatment - Fresh Frozen Plasma,
Factor Concentrates, Cryoprecipitate and Other Treatments -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2022 through 2030 and % CAGR
Table 36: France Historic Review for Rare Hemophilia Factors by
Treatment - Fresh Frozen Plasma, Factor Concentrates,
Cryoprecipitate and Other Treatments Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2014 through
2021 and % CAGR
Table 37: France 16-Year Perspective for Rare Hemophilia
Factors by Treatment - Percentage Breakdown of Value Sales for
Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and
Other Treatments for the Years 2014, 2023 & 2030
GERMANY
Rare Hemophilia Factors Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Germany for 2023 (E)
Table 38: Germany Recent Past, Current & Future Analysis for
Rare Hemophilia Factors by Treatment - Fresh Frozen Plasma,
Factor Concentrates, Cryoprecipitate and Other Treatments -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2022 through 2030 and % CAGR
Table 39: Germany Historic Review for Rare Hemophilia Factors
by Treatment - Fresh Frozen Plasma, Factor Concentrates,
Cryoprecipitate and Other Treatments Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2014 through
2021 and % CAGR
Table 40: Germany 16-Year Perspective for Rare Hemophilia
Factors by Treatment - Percentage Breakdown of Value Sales for
Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and
Other Treatments for the Years 2014, 2023 & 2030
ITALY
Table 41: Italy Recent Past, Current & Future Analysis for Rare
Hemophilia Factors by Treatment - Fresh Frozen Plasma, Factor
Concentrates, Cryoprecipitate and Other Treatments -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2022 through 2030 and % CAGR
Table 42: Italy Historic Review for Rare Hemophilia Factors by
Treatment - Fresh Frozen Plasma, Factor Concentrates,
Cryoprecipitate and Other Treatments Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2014 through
2021 and % CAGR
Table 43: Italy 16-Year Perspective for Rare Hemophilia Factors
by Treatment - Percentage Breakdown of Value Sales for Fresh
Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other
Treatments for the Years 2014, 2023 & 2030
UNITED KINGDOM
Rare Hemophilia Factors Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in the United Kingdom for 2023 (E)
Table 44: UK Recent Past, Current & Future Analysis for Rare
Hemophilia Factors by Treatment - Fresh Frozen Plasma, Factor
Concentrates, Cryoprecipitate and Other Treatments -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2022 through 2030 and % CAGR
Table 45: UK Historic Review for Rare Hemophilia Factors by
Treatment - Fresh Frozen Plasma, Factor Concentrates,
Cryoprecipitate and Other Treatments Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2014 through
2021 and % CAGR
Table 46: UK 16-Year Perspective for Rare Hemophilia Factors by
Treatment - Percentage Breakdown of Value Sales for Fresh
Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other
Treatments for the Years 2014, 2023 & 2030
REST OF EUROPE
Table 47: Rest of Europe Recent Past, Current & Future Analysis
for Rare Hemophilia Factors by Treatment - Fresh Frozen Plasma,
Factor Concentrates, Cryoprecipitate and Other Treatments -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2022 through 2030 and % CAGR
Table 48: Rest of Europe Historic Review for Rare Hemophilia
Factors by Treatment - Fresh Frozen Plasma, Factor
Concentrates, Cryoprecipitate and Other Treatments Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2014 through 2021 and % CAGR
Table 49: Rest of Europe 16-Year Perspective for Rare
Hemophilia Factors by Treatment - Percentage Breakdown of Value
Sales for Fresh Frozen Plasma, Factor Concentrates,
Cryoprecipitate and Other Treatments for the Years 2014, 2023 &
2030
ASIA-PACIFIC
Rare Hemophilia Factors Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Asia-Pacific for 2023 (E)
Table 50: Asia-Pacific Recent Past, Current & Future Analysis
for Rare Hemophilia Factors by Treatment - Fresh Frozen Plasma,
Factor Concentrates, Cryoprecipitate and Other Treatments -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2022 through 2030 and % CAGR
Table 51: Asia-Pacific Historic Review for Rare Hemophilia
Factors by Treatment - Fresh Frozen Plasma, Factor
Concentrates, Cryoprecipitate and Other Treatments Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2014 through 2021 and % CAGR
Table 52: Asia-Pacific 16-Year Perspective for Rare Hemophilia
Factors by Treatment - Percentage Breakdown of Value Sales for
Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and
Other Treatments for the Years 2014, 2023 & 2030
REST OF WORLD
Table 53: Rest of World Recent Past, Current & Future Analysis
for Rare Hemophilia Factors by Treatment - Fresh Frozen Plasma,
Factor Concentrates, Cryoprecipitate and Other Treatments -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2022 through 2030 and % CAGR
Table 54: Rest of World Historic Review for Rare Hemophilia
Factors by Treatment - Fresh Frozen Plasma, Factor
Concentrates, Cryoprecipitate and Other Treatments Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2014 through 2021 and % CAGR
Table 55: Rest of World 16-Year Perspective for Rare Hemophilia
Factors by Treatment - Percentage Breakdown of Value Sales for
Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and
Other Treatments for the Years 2014, 2023 & 2030
IV. COMPETITION
Read the full report: https://www.reportlinker.com/p06032737/?utm_source=GNW
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001
